NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course by Nelson, B et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids
versus placebo in young people at ultra-high risk of psychotic
disorders-medium-term follow-up and clinical course
Nelson, B; Amminger, G P; Yuen, H P; Markulev, C; Lavoie, S; Schäfer, M R; Hartmann, J A;
Mossaheb, N; Schlögelhofer, M; Smesny, S; Hickie, I B; Berger, Gregor; Chen, E Y H; de Haan, L;
Nieman, D H; Nordentoft, M; Riecher-Rössler, A; Verma, S; Thompson, A; Yung, A R; McGorry, P D
Abstract: This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled
trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients.
Primary outcomes of interest were transition to psychosis and symptomatic and functional outcome.
A secondary aim was to investigate clinical predictors of medium-term outcome. Three hundred four
UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and
Europe. The intervention consisted of 1.4 g/daily of omega-3 PUFA or placebo, plus up to 20 sessions
of cognitive-behavioural case management (CBCM), over the 6-month study period, with participants
receiving further CBCM sessions on basis of need between months 6-12. Mean time to follow-up was
3.4 (median = 3.3; SD = 0.9) years. There was a modest increase in transitions between 12-month and
medium-term follow-up (11-13%) and substantial improvement in symptoms and functioning between
baseline and follow-up, with no differences between the treatment groups. Most improvement had been
achieved by end of the intervention. 55% of the sample received mental health treatment between end
of intervention and follow-up. Omega-3 PUFA did not provide additional benefits to good quality psy-
chosocial intervention over the medium term. Although most improvement had been achieved by end of
intervention the substantial rates of post-intervention mental health service use indicate longer-term clin-
ical need in UHR patients. The post-intervention phase treatment or the longer-term effect of CBCM, or
a combination of the two, may have contributed to maintaining the gains achieved during the intervention
phase and prevented significant deterioration after this time.
DOI: https://doi.org/10.1038/s41537-018-0052-x
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-158238
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Nelson, B; Amminger, G P; Yuen, H P; Markulev, C; Lavoie, S; Schäfer, M R; Hartmann, J A; Mossaheb,
N; Schlögelhofer, M; Smesny, S; Hickie, I B; Berger, Gregor; Chen, E Y H; de Haan, L; Nieman, D
H; Nordentoft, M; Riecher-Rössler, A; Verma, S; Thompson, A; Yung, A R; McGorry, P D (2018).
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people
at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course. npj Schizophrenia,
4:11.
DOI: https://doi.org/10.1038/s41537-018-0052-x
2
ARTICLE OPEN
NEURAPRO: a multi-centre RCT of omega-3
polyunsaturated fatty acids versus placebo in young people at
ultra-high risk of psychotic disorders—medium-term follow-up
and clinical course
B. Nelson1,2, G. P. Amminger1,2,3, H. P. Yuen1,2, C. Markulev1,2, S. Lavoie1,2, M. R. Schäfer1,3, J. A. Hartmann1,2, N. Mossaheb4,
M. Schlögelhofer3, S. Smesny5, I. B. Hickie6, G. Berger7, E. Y. H. Chen8, L. de Haan9, D. H. Nieman9, M. Nordentoft10, A. Riecher-Rössler11,
S. Verma12, A. Thompson1,13,14, A. R. Yung1,15,16 and P. D. McGorry1,2
This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated
fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients. Primary outcomes of interest were transition to psychosis and
symptomatic and functional outcome. A secondary aim was to investigate clinical predictors of medium-term outcome. Three
hundred four UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and Europe. The
intervention consisted of 1.4 g/daily of omega-3 PUFA or placebo, plus up to 20 sessions of cognitive-behavioural case
management (CBCM), over the 6-month study period, with participants receiving further CBCM sessions on basis of need between
months 6–12. Mean time to follow-up was 3.4 (median= 3.3; SD= 0.9) years. There was a modest increase in transitions between
12-month and medium-term follow-up (11–13%) and substantial improvement in symptoms and functioning between baseline and
follow-up, with no differences between the treatment groups. Most improvement had been achieved by end of the intervention.
55% of the sample received mental health treatment between end of intervention and follow-up. Omega-3 PUFA did not provide
additional beneﬁts to good quality psychosocial intervention over the medium term. Although most improvement had been
achieved by end of intervention the substantial rates of post-intervention mental health service use indicate longer-term clinical
need in UHR patients. The post-intervention phase treatment or the longer-term effect of CBCM, or a combination of the two, may
have contributed to maintaining the gains achieved during the intervention phase and prevented signiﬁcant deterioration after this
time.
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INTRODUCTION
The ﬁrst episode of psychosis is typically preceded by a period of
initially subtle and relatively non-speciﬁc symptoms followed by a
prodromal period characterised by sub-threshold positive symp-
toms and functional difﬁculties.1 We introduced the “ultra-high
risk” (UHR) criteria more than two decades ago in order to
prospectively identify young people at incipient risk of progres-
sion to full-threshold psychosis.2,3 A considerable body of research
(>1500 studies) has validated the UHR criteria, examined
predictors and mechanisms of onset of psychotic disorder within
this clinical population, and enabled trials of a range of treatments
aimed at improving symptoms and functioning levels, and
reducing the risk of progression (transition) to psychotic disorder.4
Twelve trials assessing psychosocial and pharmacological
interventions, alone or in combination, have been conducted in
UHR cohorts. Meta-analyses have shown that these interventions
are effective, with an overall risk reduction of transition to
psychosis of 54% at 12 months, with a number needed to treat
(NNT) of 8.5–7 All treatments in these studies appeared to reduce
the risk of progression to psychosis, at least during the ﬁrst
6–12 months. In line with the clinical staging model,8–12 during
the earliest stage of illness, safer interventions, such as long-chain
omega-3 polyunsaturated fatty acids (PUFA) and cognitive
behavioural therapy (CBT), are regarded as the preferred option
for ﬁrst-line treatment. CBT has been found to be effective in
many, though not all, of the published trials.13–19 The most striking
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result from the trials to date was the ﬁnding that omega-3 PUFA
were greatly superior to placebo in reducing transition risk, and
psychiatric morbidity in general, not only during the treatment
period, but also for a prolonged period (median 6.7 years)
subsequently.20,21 Omega-3 PUFA are safe, provide broad-
spectrum health beneﬁts, and represent a simple and relatively
inexpensive treatment strategy.
We therefore attempted to replicate this ﬁnding from a single
site trial in a larger cohort of 304 UHR participants across 10 sites
internationally (the “NEURAPRO” study).22,23 At the 12-month
follow-up, we observed no difference in transition rates between
the two groups (p= .76), with both groups improving on clinical
and functioning measures.22 The failure to replicate the original
study may have been due the lack of efﬁcacy of omega-3 PUFA in
this patient population. However, other possible reasons are that
the lower than expected transition rate (~11% across groups)
prevented a test of the efﬁcacy of this treatment and that the
other treatments received in both groups (cognitive-behavioural
case management (CBCM) and antidepressant medication) may
have introduced a ceiling effect beyond which omega-3 PUFA,
even if effective, could not be shown to confer additional
beneﬁt.22 CBCM was not provided in the original study and the
rate of antidepressant prescription was lower in that study (10%
compared to 62% in the current study.) In the current paper, we
report a medium-term follow-up of the NEURAPRO study sample
in order to determine if there was an increase in the rate of
transition to psychotic disorder after cessation of treatment.
Clinical and functional outcomes in the two treatment groups, as
well as baseline predictors of outcome, were also of interest.
Previous medium-term outcome studies of UHR intervention
trials have varied in their ﬁndings. The ﬁrst medium-term follow-
up found that the beneﬁts observed at 6 months of combined
risperidone and CBT compared to “needs based intervention” did
not persist at 3–4-year follow-up.24 Morrison and colleagues14
reported that cognitive therapy was superior to monitoring over 1
year. However, at 3-year follow-up, cognitive therapy was no
longer superior in preventing transition,15 although it was found
to be associated with a reduced likelihood of being prescribed
antipsychotic medication. A study of olanzapine versus placebo
showed trend-level beneﬁts for reducing transition rate in favour
of olanzapine after 12 months, although the difference did not
reach statistical signiﬁcance.25 At 2-year follow-up transition rate
did not differ between the two groups.26 Bechdolf and
colleagues27 reported that an integrated psychological interven-
tion was superior to supportive counselling in high-risk patients at
24-month follow-up. Ising and colleagues18 reported beneﬁts in
favour of CBT compared to treatment as usual at 4-year follow-up,
both in terms of transition rate and remission from UHR status.
When pooled together, the medium-term outcome studies
(24–48 months) have shown beneﬁts in favour of speciﬁc
interventions compared to comparison conditions, with the
transition risk being reduced by 36% and a NNT of 12.5
The aim of the current study was to investigate the medium-
term outcome (transition rate, symptomatic, and functional
outcome) of the NEURAPRO cohort. While the equally positive
outcomes of the two treatment groups (low transition rate,
symptomatic and functional improvement) achieved at 12-month
follow-up may have been due to the CBCM and/or antidepressant
medication received in both groups rather than due to the trial
intervention (omega-3 PUFA), it was of interest to investigate
whether these beneﬁts were maintained over the medium term or
whether there was deterioration in clinical outcomes after
cessation of treatment. Secondary aims were to investigate
baseline clinical predictors of medium-term outcome and the
relationship between clinical measures at the end of the
intervention period and symptoms/functioning at medium-term
follow-up.
RESULTS
Study sample—follow-up
The cohort consisted of 304 participants (153 assigned to omega-3
PUFA treatment, 151 to placebo). Baseline characteristics are
presented in McGorry et al.22 Medium-term follow-up data were
collected for 270 cases (89% of the sample; Fig. 1). eTable 1
presents details of the type of follow-up assessments conducted.
Mean time to follow-up was 3.4 years (SD= 0.9 years; median=
3.3 years). The follow-up time range was 1.5–5.7 years (25th
percentile= 2.7 years, 75th percentile= 4.0 years). There were no
baseline differences on demographic or clinical measures
between those who were followed-up vs. those who were lost
to follow-up (data available upon request).
One hundred thirty-three participants (55%) had received
mental health treatment between end of the study period and
medium-term follow-up. These consisted of: general mental
health services (n= 98, 41%), hospital inpatient admissions (n=
26, 11%), UHR services (n= 14, 6%), community health services (n
= 13, 5%), drug and alcohol services (n= 4, 2%), forensic services
(n= 1, 0.4%), and other services (n= 42, 18%). Information on
pharmaceutical treatment was available for 240 cases (eTable 2).
Excluded
N=673
Screened
N=977
Randomized*
N=304
Placebo
N=151 analysed
Lost to follow-up
• withdrew  n=18
• unable to contact n=22
Lost to follow-up
• withdrew  n=14
• unable to contact n=24
• pregnant n=1
Omega-3 PUFA
N=153 analysed
Completed
n=114 
Transioned
n=17 
Completed
n=111
Transioned
n=15
• ineligible n=418
• refused n=155
• unable to seek 
consent n=100
*Randomizaon was straﬁed by site and MADRS score (<21 and ≥21)
+ N/% of follow-up data on the primary outcome
N=137 (91%)+N=133 (87%)+
12-month follow up
Medium-term follow up
Fig. 1 CONSORT diagram of participant distribution
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Outcomes
Primary outcome measure. At the medium-term follow-up, 40
participants (13% of the sample) were known to have transitioned
to psychosis. Nineteen of these transitioned cases were from the
omega-3 PUFA-treated group (12%) and 21 from the placebo-
treated group (14%). Of the 40 transitioned cases, 31 (77.5%) were
determined using the CAARMS, 6 (15%) were clinician-deter-
mined, and 3 (7.5%) were determined using hospital records.
eTable 3 presents the time to transition by treatment group. The
maximum time to transition was 4.3 years.
The survival curves comparing transition rates of the two
treatment groups are shown in Fig. 2. A stratiﬁed log-rank test was
conducted on these survival curves, adjusting for the effects of the
two stratifying factors (site and baseline MADRS score). Site had
three levels (Melbourne: n= 106, Vienna: n= 72, and other sites:
n= 126). The baseline MADRS score was divided into two levels in
randomisation:<21 and ≥21. The stratiﬁed log-rank test indicated
that there was no signiﬁcant difference between the two
treatment groups in transition rates (p= 0.77). Cox regression
was also used to compare the transition rates with site and MADRS
score as stratifying variables. The hazard ratio of omega-3 PUFA vs.
placebo was 0.91 (95% CI= 0.41–1.70), p= 0.77.
Secondary outcome measures. General linear model analysis was
used to compare the two treatments on symptom and functioning
measures at medium-term follow-up with the corresponding
baseline score, site and baseline MADRS score as covariates. As the
follow-up time had a substantial range, its effect was accounted
for as a factor of three levels (≤3 years, 3–4 years, and >4 years
from baseline). In order to examine whether the difference
between the two treatments varied between the different levels of
follow-up time, the interaction between follow-up time and
treatment was also analysed.
All symptom and functioning measures showed improvement
between baseline and medium-term follow-up (Table 1). The p-
values for the interaction term (p-value 1) of all the measures were
non-signiﬁcant, indicating that the difference between the two
treatments did not vary between different follow-up times. The p-
values for treatment (p-value 2) were also non-signiﬁcant for all
measures, indicating that the two treatments did not differ in their
effects. Approximately 50% of cases for whom data were available
(n= 166) had remitted from UHR status, with no difference in
remission rates between the treatment groups (49.4% in the
omega-3 PUFA condition, 53.2% in the placebo condition; p=
0.44).
Most improvement on the symptom and functioning measures
appeared to have been achieved by end of the intervention
period (12 months), with only minimal further improvement
between 12-month and medium-term follow-up. For example, the
mean BPRS score across both treatment groups reduced by 7.8
(SD= 8.9) points by 12 months and by a further 1.5 by points by
medium-term follow-up; mean SANS score reduced by 6.9 (SD=
11.7) points by 12 months and the same at medium-term follow-
up; mean MADRS score reduced by 9.3 points (SD= 9.5) by
12 months and by a further 0.4 points at medium-term follow-up;
mean SOFAS score increased by 14.5 points (SD= 18) by
12 months and by a further 0.6 points by medium-term follow-up.
Baseline predictors of transition to psychosis
The list of potential predictors included demographic variables,
symptom and functioning measures, and recruiting site. As in the
other analyses, recruiting site was treated as a factor of three
levels (Melbourne, Vienna, Other sites) with Melbourne used as
the reference level. The association between each variable and
transition risk was tested individually using Cox regression (Table
2).
A stepwise cox regression was then performed to analyse the
predictive value of the variables after adjusting for each other. This
analysis resulted in total BPRS score (p= 0.0000002), ethnicity (p
= 0.002), and migrant status (p= 0.033) being selected as
independent predictors of transition, with CAARMS Disorganised
Speech, BPRS Psychotic sub-scale, BPRS Anxiety, SANS total, and
SANS sub-scales, Global Functioning (Social) score no longer
remaining signiﬁcant predictive variables. The ﬁnding of ethnicity
and migrant status as predictive seemed to be driven by higher
transition risk among non-Caucasian, non-migrants. This group
showed a higher hazard ratio for transition to psychosis than
Caucasian non-migrants (HR= 5.98, 95% CI for HR= 2.08–16.61),
Caucasian migrants (10.62, 95% CI for HR= 2.04–55.25), and non-
Caucasian migrants (HR= 5.08, 95% CI for HR= 1.22–21.19). This
ﬁnding seems to be accounted for by the fact that the sites most
highly represented by non-Caucasian non-migrants (Hong Kong
and Singapore sites) had a somewhat higher transition rate (16%)
than the other sites over the medium term. However, the strength
and precision of this ﬁnding is limited by the small sample sizes of
these sites, as indicated by the wide 95% CIs.
Baseline predictors of functioning at medium-term follow-up
A general linear model was used to test the association between
each baseline variable and functioning (SOFAS score) at follow-up
(see Table 3). The same variables were included as above, as well
as time to follow-up (treated as a factor of three levels: ≤3 years,
3–4 years, and >4 years from baseline).
A stepwise procedure was again used to choose predictive
baseline variables after adjusting for each other. The variables
identiﬁed were BPRS Anxiety subscale, the Global Functioning
(Role) score, SANS Attention subscale and site (eTable 4), with the
BPRS psychotic subscale, YMRS, MADRS, and Global Functioning
(Social) score no longer remaining as signiﬁcant predictors. The
Melbourne site showed lower follow-up SOFAS scores than the
Vienna site (11 points) and other sites (8.6 points). The model
using these three variables explained 25.3% of the variation in
SOFAS scores.
Baseline and end of treatment (12-month) clinical measures in
relation to medium-term follow-up
The correlations of clinical measures between medium-term
follow-up and baseline and end of treatment (12 month) are
presented in eTable 5. On the whole, both sets of correlations
were moderate in magnitude, with the 12-month medium-term
follow-up correlations stronger than the baseline medium-term
follow-up correlations. This indicates that symptomatology and
functioning levels at the end of treatment were a reasonably good
indicator of the same several years later.
Fig. 2 Survival curves showing transition to psychosis in the two
treatment groups
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DISCUSSION
This paper reports a medium-term follow-up of an intervention
trial of omega-3 PUFA plus CBCM vs. placebo plus CBCM in a UHR
sample. The ﬁndings indicated a non-trivial but modest increase in
proportion of known transitions between 12-month and medium-
term follow-up (11–13%), with no signiﬁcant difference in
transition rate between the two treatment groups. On average,
participants improved in their clinical symptomatology/function-
ing between baseline and medium-term follow-up, regardless of
treatment condition, and approximately half remitted from UHR
status. In fact, the group-level improvement was substantial, with
clinical ratings indicating improvement from moderate/serious
symptomatology and functional impairment at entry to mild
symptoms and functional impairment at follow-up. On the whole,
this improvement appeared to have been achieved by the end of
Table 1. General linear model analysis comparing placebo and omega-3 PUFA groups in terms of change between baseline and follow-up after
adjusting for baseline score, site, and baseline MADRS score
n Baseline
(mean)
Medium-term follow-up
(mean)
Medium-term—BL change
(mean)
Medium-term—BL change
(SD)
p-value 1 p-value 2
CAARMS
unusual thought content
Placebo 77 5.6 1.9 −3.8 4.1 0.101 0.638
Omega-3 PUFA 84 4.7 1.4 −3.2 4.5
CAARMS
non-bizarre ideas
Placebo 77 6.7 3.0 −3.7 3.9 0.356 0.788
Omega-3 PUFA 83 7.2 3.0 −4.1 4.5
CAARMS
perceptual abnormalities
Placebo 77 6.5 3.2 −3.3 3.7 0.972 0.370
Omega-3 PUFA 84 6.3 2.8 −3.5 3.4
CAARMS
disorganised speech
Placebo 77 3.5 0.9 −2.5 3.2 0.705 0.646
Omega-3 PUFA 82 3.7 1.1 −2.6 3.9
BPRS total
Placebo 70 41.4 32.1 −9.3 10.0 0.348 0.861
Omega-3 PUFA 71 41.6 32.3 −9.4 10.1
BPRS psychotic subscale
Placebo 76 8.5 5.3 −3.2 3.4 0.253 0.871
Omega-3 PUFA 76 8.2 5.3 −2.9 2.9
BPRS anxiety
Placebo 76 3.5 2.1 −1.4 1.7 0.862 0.816
Omega-3 PUFA 76 3.2 2.1 −1.1 1.6
SANS
Placebo 69 16.4 9.8 −6.6 12.3 0.931 0.495
Omega-3 PUFA 71 18.5 11.5 −7.1 12.3
YMRS
Placebo 70 2.7 1.9 −0.8 2.8 0.572 0.286
Omega-3 PUFA 71 3.2 1.5 −1.7 3.7
MADRS
Placebo 75 19.5 9.8 −9.7 10.5 0.589 0.663
Omega-3 PUFA 76 20.6 10.9 −9.7 10.4
SOFAS
Placebo 89 54.1 69.4 15.3 16.5 0.366 0.518
Omega-3 PUFA 91 52.7 67.5 14.8 18.3
Global functioning—social scale
Placebo 76 6.6 7.4 0.8 1.6 0.104 0.483
Omega-3 PUFA 76 6.6 7.2 0.6 1.4
Global functioning—role scale
Placebo 76 6.0 7.3 1.3 1.7 0.468 0.385
Omega-3 PUFA 76 6.0 7.1 1.0 1.6
n number with baseline and medium-term follow-up data, BL baseline, SD standard deviation of change score, p-value 1 p-value for the interaction between
follow-up time and treatment, p-value 2 p-value for treatment, CAARMS Comprehensive Assessment of At-Risk Mental State, BPRS Brief Psychiatric Rating Scale,
SANS Scale for the Assessment of Negative Symptoms, MADRSMontgomery-Asberg Depression Rating Scale, YMRS Young Mania Rating Scale, SOFAS Social and
Occupational Functioning Scale, PUFA polyunsaturated fatty acids
Note: CAARMS scales were calculated as the sum of the intensity and frequency scales
NEURAPRO: a multi-centre RCT of
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the intervention period (12 months), with only minor further
improvement between 12-month and medium-term follow-up.
The strongest independent baseline predictor of transition to
psychosis was general psychopathology levels (total BPRS score).
Participants of a non-Caucasian non-migrant background had a
somewhat higher transition risk, which seemed to be a site effect.
Baseline anxiety, negative symptoms (particularly attention
disturbances), and poor role functioning independently predicted
poor functional outcome. A further site effect was also apparent,
with participants from the Melbourne site showing substantially
poorer functioning at medium-term follow-up.
The modest increase in transition rate after cessation of speciﬁc
targeted intervention is consistent with some previous medium-
term follow-up studies.18,27 However, it is inconsistent with other
studies15,24,26 which reported a substantial escalation in transition
rate after end of treatment and concluded that the beneﬁts of
speciﬁc intervention were only apparent during the treatment
phase. There are a number of possible reasons for the only modest
increase observed in the current study. All participants received
CBCM during the intervention phase. The CBT aspect of this
intervention was speciﬁcally directed toward cognitive restructur-
ing, building resilience against stress, and stress management.23
These aspects of the psychotherapy may have been protective
over the longer term, rather than just dealing with immediate
mental health and contextual difﬁculties during treatment. This is
consistent with the higher medium-term transition rate in the
Hong Kong and Singapore sites compared to the other sites,
because these sites provided a lower number of CBCM sessions
(mean of 7.2 sessions compared to 10.6 sessions among the other
sites). The possibility of the effect of CBCM, with omega-3 PUFAs
not conferring additional beneﬁts, is indicated by the lack of
difference in transition rate between the treatment groups at 12-
month and medium-term follow-up, as well as by the substantial
clinical improvements achieved in both groups by the end of the
intervention phase.
Approximately half (55%) of the sample for whom data were
available received ongoing mental health treatment after the end
of the study intervention period, which may have had the effect of
maintaining the gains achieved during the intervention phase as
Table 2. Cox regression of the association between transition to
psychosis and each baseline variable individually
n β se (β) p-value
Age 304 0.044 0.032 0.168
Gender 304 0.017 0.317 0.957
Ethnicity (Caucasian vs. non-
Caucasian)
297 0.367 0.381 0.336
Years of education 297 −0.033 0.031 0.296
DUS 284 0.00016 0.00012 0.175
Log (DUS) 284 −0.034 0.104 0.747
CAARMS unusual thought content 304 0.024 0.044 0.587
CAARMS non-bizarre ideas 304 −0.017 0.049 0.725
CAARMS perceptual abnormalities 303 −0.015 0.059 0.794
CAARMS disorganised speech 299 0.109 0.051 0.033
BPRS total 296 0.061 0.013 0.000005
BPRS psychotic subscale 294 0.134 0.062 0.030
BPRS anxiety 296 0.354 0.107 0.00096
SANS total 295 0.035 0.010 0.001
SANS affective ﬂattening or
blunting
295 0.069 0.023 0.003
SANS alogia 295 0.107 0.048 0.024
SANS avolition-apathy 295 0.142 0.053 0.008
SANS anhedonia-asociality 295 0.076 0.036 0.038
SANS attention 294 0.166 0.086 0.054
YMRS total 294 0.032 0.053 0.547
MADRS total 304 0.024 0.018 0.187
SOFAS 298 −0.023 0.013 0.072
Global functioning—social scale 296 −0.353 0.124 0.004
Global functioning—role scale 296 −0.064 0.101 0.526
Site: Vienna vs. Melbourne 304 −0.703 0.521 0.177
Site: Other sites vs. Melbourne 304 0.433 0.349 0.216
Migrant status (yes vs. no) 297 −0.662 0.479 0.167
n number with baseline and medium-term follow-up data, DUS duration of
untreated symptoms prior to study entry, CAARMS Comprehensive
Assessment of At-Risk Mental State, BPRS Brief Psychiatric Rating Scale,
SANS Scale for the Assessment of Negative Symptoms, MADRS
Montgomery-Asberg Depression Rating Scale, YMRS Young Mania Rating
Scale, SOFAS Social and Occupational Functioning Scale. Sub-scales are also
reported when total scale scores were signiﬁcant predictors
Table 3. General linear model analysis results for the association
between SOFAS score at medium-term follow-up and each baseline
variable individually
n β se (β) p-value
Age 180 0.072 0.265 0.785
Gender 180 −0.202 2.377 0.932
Race (Caucasian vs. non-Caucasian) 180 1.306 3.609 0.718
Years of education 180 −0.059 0.237 0.806
DUS 175 −0.002 0.001 0.028
Log(DUS) 175 −0.963 0.767 0.211
CAARMS unusual thought content 180 −0.141 0.330 0.670
CAARMS non-bizarre ideas 180 −0.091 0.384 0.814
CAARMS perceptual abnormalities 179 −0.085 0.499 0.865
CAARMS disorganised speech 176 −0.140 0.375 0.709
BPRS total 180 −0.509 0.115 0.00002
BPRS psychotic subscale 179 −1.101 0.434 0.012
BPRS anxiety subscale 180 −2.954 0.729 0.00008
SANS total 179 −0.308 0.083 0.000
SANS affective ﬂattening or blunting 179 −0.312 0.206 0.132
SANS alogia 179 −0.582 0.395 0.143
SANS avolition-apathy 179 −1.726 0.364 0.000004
SANS anhedonia-asociality 179 −0.911 0.265 0.0007
SANS attention 179 −3.122 0.636 0.000002
YMRS 180 −1.014 0.421 0.017
MADRS 180 −0.517 0.128 0.00008
Global functioning—social scale 180 3.606 0.897 0.00009
Global functioning—role scale 180 3.025 0.766 0.0001
Site: Vienna vs. Melbourne 180 11.319 2.807 0.00008
Site: Other sites vs. Melbourne 180 8.121 2.672 0.003
Follow-up time: 3–4 vs. ≤3 years 180 −2.228 2.710 0.412
Follow-up time: >4 vs. ≤3 years 180 −5.846 3.026 0.055
Migrant status (yes vs. no) 180 −0.862 2.870 0.764
n number with baseline and medium-term follow-up data, DUS duration of
untreated symptoms prior to study entry, CAARMS Comprehensive
Assessment of At-Risk Mental State, BPRS Brief Psychiatric Rating Scale,
SANS Scale for the Assessment of Negative Symptoms, MADRS
Montgomery-Asberg Depression Rating Scale, YMRS Young Mania Rating
Scale, SOFAS Social and Occupational Functioning Scale. Sub-scales are also
reported when total scale scores were signiﬁcant predictors
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well as preventing deterioration. A substantial proportion of the
sample (62%) received antidepressants during the intervention
phase, which may had both an immediate effect on lowering the
transition rate (improving mood and thereby indirectly reducing
faulty appraisal of anomalous experiences linked to future
psychosis28) and conferred beneﬁt over the longer term
(modulating response to environmental stress/adversity29,30 and
possibly also via a neuroprotective route31–33). The use of
antidepressants in approximately 20% of participants over the
follow-up period may also have contributed to preventing the
transition rate from escalating more substantially over this period,
as well as possibly also contributing to the ongoing improvement
in psychopathology and functioning. Additionally, approximately
10% of the sample used antipsychotic medication over the follow-
up period (although this was mainly in participants who
transitioned to psychosis). Finally, the use of omega-3 supple-
mentation or change in dietary habits was not controlled after the
study intervention period, which may have contributed to lack of
difference between the treatments groups at medium-term
outcome and the modest overall transition rate, if indeed
omega-3 PUFAs do have a protective effect in high-risk patients.
Although most clinical improvement seemed to have been
achieved by the end of the intervention period (12 months), the
high proportion of the sample who received (psychosocial and
pharmacological) mental health support after the intervention
period indicates ongoing clinical need in this population after 1
year of care.
The possibility of this sample not being sufﬁciently enriched for
psychosis risk must also be considered. In other words, it is
possible that the modest transition rate was not due to the
reasons outlined above, but may have been observed regardless
of the type of treatment provided, or indeed whether treatment
was provided or not. Earlier intervention,34 pre-screening char-
acteristics such as referral pathways and demographic character-
istics,35–37 and changing symptom proﬁles in cohorts38 have all
been reported as playing contributing roles to the lower transition
rate in recently recruited UHR cohorts.
The prediction analysis conducted in this report reafﬁrms39 the
importance of time period of observation in determining predictor
variables/models. Speciﬁcally, different baseline variables pre-
dicted short (12-month) vs. medium-term (>2 year) outcome in
this sample. Baseline depression was a strong predictor of
transition by 12 months,22 with a MADRS cut-off score of 14
distinguishing between a 16.5 vs. 0% 12-month transition rate,
whereas depression did not appear as a signiﬁcant predictor over
the medium term, with general psychopathology scores playing a
stronger predictive role. This suggests, from a clinical point of
view, that inferring level of risk based on clinical characteristics of
new patients should not be based solely on research into
predictors of short-term outcome, but also on variables that
predict the longer-term outcome of patients. For example, if
results from the current cohort were to be used to form a clinical
risk calculator,40 entry depression scores might have identiﬁed
those at short-term risk but missed those at medium-term risk.
The results also show, as one would expect, that clinical state over
the medium term appears to be better predicted by clinical state
at the end of 12 months of treatment than by baseline symptom
and functioning scores.
Baseline anxiety, poor role functioning, and negative symptoms
(particularly attention disturbances) predicted poor functional
outcome. The predictive role of negative symptoms is consistent
with previous ﬁndings in UHR cohorts.39,41–43 While anxiety is
known to be associated with compromised functioning in adult
populations,44,45 its role may have been somewhat neglected in
psychosis risk research and youth mental health more broadly.
The predictive role of anxiety, general psychopathology, depres-
sion (over the short term) and negative symptoms for poor
outcome (psychosis onset and poor functioning) reinforces the
value of a broad, formulation-based target of intervention for the
UHR group.46 Although attenuated positive psychotic symptoms
are a common feature of the population (apart from the small
minority only meeting transient psychosis or genetic risk criteria),
a range of general psychopathological characteristics play a role in
predicting poor outcome and should therefore be a focus of
intervention.
Functioning levels at medium-term outcome were found to vary
by recruitment site, with the Melbourne site showing poorer
functioning than other sites. This may have been due to socio-
economic factors, given that a large portion of the Melbourne
site’s catchment area is of deprived socio-economic status
compared to the other recruiting sites. This differential outcome
by site does not seem to have been due to differences in
treatment received over the follow-up period, with 55–60% of
participants at each recruitment site receiving treatment over this
period.
Given the negative ﬁndings of this trial, future work needs to
further investigate whether omega-3 PUFA may play a role in
treatment of this patient population. Other trials are currently
underway to this end (https://clinicaltrials.gov/ct2/show/
NCT01429454; https://clinicaltrials.gov/ct2/show/record/
NCT02597439). The efﬁcacy of omega-3 PUFAs in sub-groups of
patients should also be investigated—for example, in those with
aberrant membrane fatty acid levels or inﬂammatory markers.
Predictive modelling in this patient population should also
incorporate time-dependent or dynamic characteristics,47,48 rather
than relying solely on baseline clinical variables, and examine
predictors of persistent or incident non-psychotic outcomes.49,50
Group-level prediction analysis, as we have conducted in the
current report, may mask important sub-group (e.g., “poor” vs.
“good” outcome) differences, which will be the focus of
subsequent reports. Finally, although a high follow-up rate
(89%) was achieved on the main outcome of interest (transition
to psychosis), availability of follow-up data on other outcomes
(59% for functioning and 41–46% for symptom measures) were
more modest. This may have introduced an attrition bias toward
more favourable outcome data, given that previous research51
indicates difﬁculty recontacting members of adolescent and
young adult psychiatric cohorts is associated with increased
presence of disorder at follow-up.
CONCLUSION
This medium-term follow-up indicated substantial improvement in
symptoms and functioning in a UHR cohort over a mean 3.4-year
follow-up period, with no difference between the omega-3 and
placebo-treated groups. Most of this improvement had been
achieved by the end of the intervention period (12 months),
although high rates of post-intervention mental health service use
indicate ongoing clinical need after this time. This post-
intervention phase intervention or the longer-term effect of
CBCM, or a combination of the two, may have contributed to
maintaining the gains achieved during the intervention phase and
prevented signiﬁcant deterioration after this time.
METHOD
Study design
This was a randomised, double-blind, placebo-controlled treatment trial of
omega-3 PUFA plus CBCM or placebo plus CBCM. Treatment was provided
for 6 months, with participants receiving further CBCM52 on the basis of
need between months 6 and 12. See Markulev et al.23 for full details of
study methodology, inclusion/exclusion criteria and interventions, and
McGorry et al.22 for the 6 and 12-month results.
The study was performed in accordance with the Declaration of
Helsinki.53 The National Health and Medical Research Council of Australia
(NHMRC) National Statement on Human Research was adhered to and
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appropriate ethical approval was obtained by each site (Melbourne,
Australia: Melbourne Health Research Ethics Committee; Sydney, Australia:
Sydney South West Area Health Service Ethics Review Committee; Basel,
Switzerland: Ethics Commission for Basel; Zurich, Switzerland: Cantonal
Ethics Commission Zurich; Jena, Germany: University Clinic Jena Ethics
Commission; Copenhagen, Denmark: Capital Region Research Ethics
Committee; Hong Kong: Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster; Vienna, Austria:
Medical University of Vienna Ethics Commission; Singapore: National
Healthcare Group Domain Speciﬁc Review Board; and Amsterdam, the
Netherlands: Academic Medical Centre Medical Ethics Committee). Written
informed consent was obtained for those younger than 17 years, parental
or guardian consent was sought. The trial was registered at the Australia
and New Zealand Clinical Trials Registry (ID 12608000475347).
Medium-term follow-up
Medium-term follow-up of the sample was conducted in 2015–2016. The
procedure consisted of the following steps to locate and recontact
participants: (1) accessing the National Death Index to determine whether
any participant had died since last contact, (2) research ﬁles, (3) public
mental health service record systems, (4) National Electoral Roll, (5)
telephone directory, (6) previous contacts, and (7) internet-based
searching. Re-contacted participants were invited to a comprehensive
face-to-face interview. If individuals did not consent to face-to-face
assessment, they were asked for a brief telephone assessment, enabling
collection of a minimum dataset. The brief assessment consisted of a sub-
set of measures, including determination of transition status and
functioning levels. When participants could not be contacted, hospital
records were consulted to collect details of public health service contact,
date of contact and diagnosis.
Outcome measures
The main outcome of interest was transition to psychosis, with transition
deﬁned on the basis of operationalized criteria and assessed with the
Comprehensive Assessment of the At-Risk Mental State (CAARMS).42
Diagnoses were determined with the Structured Clinical Interview for DSM-
IV-TR Axis I Disorders. If CAARMS data were not available, the public mental
health records were accessed to determine if the participant had
developed a psychotic disorder. Secondary outcome measures included
the Brief Psychiatric Rating Scale (BPRS),54 the Scale for the Assessment of
Negative Symptoms (SANS),55 the MADRS,56 the Young Mania Rating Scale
(YMRS),57 the SOFAS,58 and the Global Functioning: Social59 and Role60
scales.
Statistical analysis
The primary analysis used the intention-to-treat approach, comparing the
difference in transition rates between the treatment groups using survival
analysis with the stratiﬁed log-rank test and Cox regression with
recruitment site and baseline Montgomery-Asberg Depression Rating
Scale (MADRS)56 score (<21 and ≥21) as stratifying factors. General linear
modelling was used to compare the secondary outcomes between the two
treatment groups. Baseline clinical predictors of outcome were examined
using stepwise cox regression. The relationship between clinical measures
at the end of the treatment phase and medium-term follow-up was
examined using Pearson correlation.
Data availability
The data that support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
ACKNOWLEDGEMENTS
This work was supported by Grant 07TGF-1102 from the Stanley Medical Research
Institute, a National Health and Medical Research Council (NHMRC) Australia Program
Grant (ID: 566529; P.D.M., I.B.H., A.R.Y., G.P.A.) and a grant from the Colonial
Foundation. B.N. was supported by an NHMRC Career Development Fellowship (ID:
1027532) and a University of Melbourne Faculty of MDHS Fellowship. P.D.M. was
supported by a Senior Principal Research Fellowship from the NHMRC (ID: 1060996).
G.P.A. and A.R.Y. were supported by NHMRC Senior Research Fellowships (ID:
1080963 and 566593).
AUTHOR CONTRIBUTIONS
Nelson and McGorry had full access to all the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis. Study concept and
design: McGorry, Nelson, Markulev, Yuen, Schaefer, Schloegelhofer, Hickie, Berger,
Chen, Nordentoft, Riecher-Rossler, Thompson, Yung, Amminger. Acquisition, analysis,
or interpretation of data: Nelson, Markulev, Yuen, Schaefer, Mossaheb, Smesny,
Hickie, Berger, Chen, de Haan, Nieman, Nordentoft, Riecher-Rossler, Verma,
Thompson, Yung, Amminger. Drafting of the manuscript: Nelson, McGorry, Yuen,
Amminger, Lavoie. Critical revision of the manuscript for important intellectual
content: Nelson, McGorry, Hartmann, Markulev, Yuen, Schaefer, Mossaheb, Schloe-
gelhofer, Smesny, Berger, Chen, de Haan, Lavoie, Nieman, Nordentoft, Riecher-
Rossler, Verma, Thompson, Yung, Amminger. Statistical analysis: Yuen, Nelson,
Amminger. Obtained funding: McGorry, Nelson, Chen, Amminger. Administrative,
technical, or material support: Lavoie, Markulev, Mossaheb, Schloegelhofer, Smesny,
Chen, Riecher-Rossler, Thompson. Study supervision: McGorry, Nelson, Lavoie,
Markulev, Yuen, Schaefer, Mossaheb, Berger, Chen, de Haan, Nieman, Nordentoft,
Riecher-Rossler, Verma, Thompson, Yung, Amminger.
ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Schizophrenia
website (https://doi.org/10.1038/s41537-018-0052-x).
Competing interests: Dr. McGorry reported receiving grant funding from National
Alliance for Research on Schizophrenia and Depression and unrestricted research
funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pﬁzer, and Novartis, as well as
honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pﬁzer,
Bristol-Myers Squibb, Roche, and the Lundbeck Institute. Drs. Nelson, Hickie, Yung,
and Amminger have received National Health and Medical Research Council
(NHMRC) funding. The remaining authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Yung, A. R. et al. Monitoring and care of young people at incipient risk of psy-
chosis. Schizophr. Bull. 22, 283–303 (1996).
2. Yung, A. R. & McGorry, P. D. The prodromal phase of ﬁrst-episode psychosis: past
and current conceptualizations. Schizophr. Bull. 22, 353–370 (1996).
3. Yung, A. R. et al. Psychosis prediction: 12-month follow up of a high-risk (“pro-
dromal”) group. Schizophr. Res. 60, 21–32 (2003).
4. Fusar-Poli, P. et al. The psychosis high-risk state: a comprehensive state-of-the-art
review. JAMA Psychiatry 70, 107–120 (2013).
5. van der Gaag, M. et al. Preventing a ﬁrst episode of psychosis: meta-analysis of
randomized controlled prevention trials of 12 month and longer-term follow-ups.
Schizophr. Res. 149, 56–62 (2013).
6. Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P. & Kendall, T. Early
interventions to prevent psychosis: systematic review and meta-analysis. Br. Med.
J. 346, f185 (2013).
7. Hutton, P. & Taylor, P. J. Cognitive behavioural therapy for psychosis prevention: a
systematic review and meta-analysis. Psychol. Med. 44, 1–20 (2013).
8. McGorry, P. & Nelson, B. Why we need a transdiagnostic staging approach to
emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry 73,
1–2 (2016).
9. McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C. & Jackson, H. J. Clinical staging
of psychiatric disorders: a heuristic framework for choosing earlier, safer and
more effective interventions. Aust. N. Z. J. Psychiatry 40, 616–622 (2006).
10. McGorry, P. D. Risk syndromes, clinical staging and DSM V: new diagnostic
infrastructure for early intervention in psychiatry. Schizophr. Res. 120, 49–53
(2010).
11. McGorry, P. D. The next stage for diagnosis: validity through utility. World Psy-
chiatry 12, 213–215 (2013).
12. McGorry, P. D. Early clinical phenotypes, clinical staging, and strategic biomarker
research: building blocks for personalized psychiatry. Biol. Psychiatry 74, 394–395
(2013).
13. Addington, J. et al. A randomized controlled trial of cognitive behavioral therapy
for individuals at clinical high risk of psychosis. Schizophr. Res. 125, 54–61 (2011).
14. Morrison, A. P. et al. Cognitive therapy for the prevention of psychosis in people
at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185, 291–297
(2004).
15. Morrison, A. P. et al. Three-year follow-up of a randomized controlled trial of
cognitive therapy for the prevention of psychosis in people at ultrahigh risk.
Schizophr. Bull. 33, 682–687 (2007).
NEURAPRO: a multi-centre RCT of
B Nelson et al.
7
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2018)  11 
16. Morrison, A. P. et al. Early detection and intervention evaluation for people at risk
of psychosis: multisite randomised controlled trial. Br. Med. J. 344, e2233 (2012).
17. van der Gaag, M. et al. Cognitive behavioral therapy for subjects at ultrahigh risk
for developing psychosis: a randomized controlled clinical trial. Schizophr. Bull.
38, 1180–1188 (2012).
18. Ising, H. K. et al. Four-year follow-up of cognitive behavioral therapy in persons at
ultra-high risk for developing psychosis: the Dutch early detection intervention
evaluation (EDIE-NL) trial. Schizophr. Bull. 42, 1243–1252 (2016).
19. Stain, H. J. et al. A randomised controlled trial of cognitive behaviour therapy
versus non-directive reﬂective listening for young people at ultra high risk of
developing psychosis: the detection and evaluation of psychological therapy
(DEPTh) trial. Schizophr. Res. 176, 212–219 (2016).
20. Amminger, G. P. et al. Long-chain omega-3 fatty acids for indicated prevention of
psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry
67, 146–154 (2010).
21. Amminger, G. P., Schafer, M. R., Schlogelhofer, M., Klier, C. M. & McGorry, P. D.
Longer-term outcome in the prevention of psychotic disorders by the Vienna
omega-3 study. Nat. Commun. 6, 7934 (2015).
22. McGorry, P. D. et al. Effect of omega-3 polyunsaturated fatty acids in young
people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized
clinical trial. JAMA Psychiatry 74, 19–27 (2017).
23. Markulev, C. et al. NEURAPRO-E study protocol: a multicentre randomized con-
trolled trial of omega-3 fatty acids and cognitive-behavioural case management
for patients at ultra high risk of schizophrenia and other psychotic disorders. Early
Interv. Psychiatry 11, 418–428 (2015).
24. Phillips, L. J. et al. Medium term follow-up of a randomized controlled trial of
interventions for young people at ultra high risk of psychosis. Schizophr. Res. 96,
25–33 (2007).
25. McGlashan, T. H. et al. Randomized, double-blind trial of olanzapine versus pla-
cebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163,
790–799 (2006).
26. McGlashan, T. H. et al. Olanzapine for treatment of the schizophrenia prodrome: 2
year results of a randomized placebo-controlled study. World J. Biol. Psychiatry 5,
146 (2004).
27. Bechdolf, A. et al. Preventing progression to ﬁrst-episode psychosis in early initial
prodromal states. Br. J. Psychiatry 200, 22–29 (2012).
28. Nelson, B. et al. Staged treatment in early psychosis: a sequential multiple
assignment randomised trial of interventions for ultra high risk of psychosis
patients. Early Interv. Psychiatry. https://doi.org/10.1111/eip.12459 (2017).
29. Fusar-Poli, P., Valmaggia, L. & McGuire, P. Can antidepressants prevent psychosis?
Lancet 370, 1746–1748 (2007).
30. Cantor-Graae, E. The contribution of social factors to the development of schi-
zophrenia: a review of recent ﬁndings. Can. J. Psychiatry 52, 277–286 (2007).
31. Chen, G. et al. Regulation of signal transduction pathways and gene expression
by mood stabilizers and antidepressants. Psychosom. Med. 61, 599–617 (1999).
32. Michael-Titus, A. T., Bains, S., Jeetle, J. & Whelpton, R. Imipramine and phenelzine
decrease glutamate overﬂow in the prefrontal cortex—a possible mechanism of
neuroprotection in major depression? Neuroscience 100, 681–684 (2000).
33. Sanchez, V. et al. The mechanisms involved in the long-lasting neuroprotective
effect of ﬂuoxetine against MDMA (‘ecstasy’)-induced degeneration of 5-HT nerve
endings in rat brain. Br. J. Pharmacol. 134, 46–57 (2001).
34. Nelson, B. et al. Further examination of the reducing transition rate in ultra high
risk for psychosis samples: the possible role of earlier intervention. Schizophr. Res.
174, 43–49 (2016).
35. Fusar-Poli, P. et al. Deconstructing pretest risk enrichment to optimize prediction
of psychosis in individuals at clinical high risk. JAMA Psychiatry 73, 1260–1267
(2016).
36. Fusar-Poli, P. et al. Why transition risk to psychosis is not declining at the OASIS
ultra high risk service: the hidden role of stable pretest risk enrichment. Schizophr.
Res. 192, 385–390 (2017).
37. Wiltink, S., Velthorst, E., Nelson, B., McGorry, P. M. & Yung, A. R. Declining tran-
sition rates to psychosis: the contribution of potential changes in referral path-
ways to an ultra-high-risk service. Early Interv. Psychiatry 9, 200–206 (2015).
38. Hartmann, J. A. et al. Declining transition rates to psychotic disorder in “ultra-high
risk” clients: investigation of a dilution effect. Schizophr. Res. 170, 130–136 (2016).
39. Nelson, B. et al. Long-term follow-up of a group at ultra high risk (“prodromal”)
for psychosis: the PACE 400 study. JAMA Psychiatry 70, 793–802 (2013).
40. Cannon, T. D. et al. An individualized risk calculator for research in prodromal
psychosis. Am. J. Psychiatry 173, 980–988 (2016).
41. Mason, O. et al. Risk factors for transition to ﬁrst episode psychosis among
individuals with ‘at-risk mental states’. Schizophr. Res. 71, 227–237 (2004).
42. Yung, A. R. et al. Mapping the onset of psychosis: the comprehensive assessment
of at-risk mental states. Aust. N. Z. J. Psychiatry 39, 964–971 (2005).
43. Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. S. Risk and protection in pro-
dromal schizophrenia: ethical implications for clinical practice and future
research. Schizophr. Bull. 32, 166–178 (2006).
44. Bijl, R. V. & Ravelli, A. Current and residual functional disability associated with
psychopathology: ﬁndings from the Netherlands Mental Health Survey and
Incidence Study (NEMESIS). Psychol. Med. 30, 657–668 (2000).
45. Joffe, H. et al. Lifetime history of depression and anxiety disorders as a predictor
of quality of life in midlife women in the absence of current illness episodes. Arch.
Gen. Psychiatry 69, 484–492 (2012).
46. Group, T. P. M. W. The PACE Clinic Manual: A Treatment Approach for Young People
at Ultra High Risk of Psychosis (Orygen Youth Health, Melbourne, 2012).
47. Yuen, H. P., Mackinnon, A. & Nelson, B. A method for analysing transition to
psychosis: joint modelling of time-to-event outcome with time-dependent pre-
dictors. Int. J. Methods Psychiatr. Res. https://doi.org/10.1002/mpr.1588 (2017).
48. Nelson, B., McGorry, P. D., Wichers, M., Wigman, J. T. W. & Hartmann, J. Moving
from static to dynamic models of the onset of mental disorder. JAMA Psychiatry
74, 528–534 (2017).
49. Lin, A. et al. Outcomes of nontransitioned cases in a sample at ultra-high risk for
psychosis. Am. J. Psychiatry 172, 249–258 (2015).
50. Woods, S. W. E. A. Lack of diagnostic pluripotentiality in patients at clinical high
risk for psychosis: speci city of comorbidity persistence and search for plur-
ipotential subgroups. Schizophr. Bull. https://doi.org/10.1093/schbul/sbx138
(2017).
51. Allott, K., Chanen, A. & Yuen, H. P. Attrition bias in longitudinal research involving
adolescent psychiatric outpatients. J. Nerv. Ment. Dis. 194, 958–961 (2006).
52. Hartmann, J. A. et al. Opening the black box of cognitive-behavioural case
management in clients with ultra-high risk for psychosis. Psychother. Psychosom.
86, 292–299 (2017).
53. World Medical, A. World Medical Association Declaration of Helsinki: ethical
principles for medical research involving human subjects. J. Am. Med. Assoc. 310,
2191–2194 (2013).
54. Overall, J. E. & Gorham, D. R. The brief psychiatric rating scale. Psychol. Rep. 10,
799–812 (1962).
55. Andreasen, N. C. Scale for the Assessment of Negative Symptoms (SANS) (University
of Iowa, Iowa City, 1983).
56. Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive
to change. Br. J. Psychiatry 134, 382–389 (1979).
57. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania:
reliability, validity and sensitivity. Br. J. Psychiatry 133, 429–435 (1978).
58. Goldman, H. H., Skodol, A. E. & Lave, T. R. Revising axis V for DSM-IV: a review of
measures of social functioning. Am. J. Psychiatry 149, 1148–1156 (1992).
59. Auther, A., Smith, C. & Cornblatt, B. Global Functioning: Social Scale (GF: Social)
(Zucker-Hillside Hospital, New York, 2006).
60. Niendam, T. A., Bearden, C. E., Johnson, J. K. & TD, C. Global Functioning: Role Scale
(GF: Role). (University of California, Los Angeles, 2006).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
NEURAPRO: a multi-centre RCT of
B Nelson et al.
8
npj Schizophrenia (2018)  11 Published in partnership with the Schizophrenia International Research Society
